ReviewPLoS pathogens2023
Advances in the treatment of invasive fungal disease.
Review in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy of probiotics in the management of oral candidiasis: an umbrella review of systematic reviews and meta-analyses.Systematic reviews · 2026Pooled it
- Efficacy of probiotics for oral candidiasis management: a systematic review.BMC oral health · 2025Pooled it
- Trial
- Dual-Targeting, Hybrid Antifungal Agents Targeting Candida albicans-An Overview.Chemical biology & drug design · 2026Review
- FrogPCSP: a propeptide cleavage site predictor for frog antimicrobial peptides.Scientific reports · 2026Article
- Research progress on self-assembled supramolecular bioactive materials from herbal natural products and their applications in anti-infection field.Materials today. Bio · 2026Review
- Comparative risk of arrhythmias associated with systemic antifungal agents: a disproportionality analysis of the FAERS database.Frontiers in pharmacology · 2026Article
- Real-World Outcomes of Amphotericin B Colloidal Dispersion as Salvage Therapy for Invasive Fungal Disease.Drug design, development and therapy · 2026Article
- Diagnosis and treatment of invasive fungal disease in children with hematological malignancies after chemotherapy: Challenges and strategies (Review).Experimental and therapeutic medicine · 2026Review
- Direct Inoculation of Pathogenic Yeasts into Mouse Lung by Trans-tracheal Instillation.Methods in molecular biology (Clifton, N.J.) · 2026Article
- A Clinical Prediction Model for Invasive Pulmonary Fungal Disease in Dialysis Patients: Development, Validation, and Pharmacist-Led Application.Infection and drug resistance · 2026Article
- Biochanin A Suppresses Growth and Biofilm Formation of Fluconazole-Resistant Candida auris.Current microbiology · 2025Article
- Antifungal Drugs for the Treatment of Invasive Fungal Infections-A Limited Therapeutic Toolbox Facing Growing Resistances.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives.Infectious disease reports · 2025Review
- Inhibition of candidalysin production by methoxy-apo-enterobactin from Streptomyces ambofaciens CJD34 as a novel antifungal strategy against Candida albicans.Journal of microbiology (Seoul, Korea) · 2025Article
- Management of Intra-Abdominal Candidiasis in Intensive Care Setting: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Sustainable Management of Major Fungal Phytopathogens in Sorghum (Journal of fungi (Basel, Switzerland) · 2025Review
- Zinc Acetate as a Cross-Linking Agent in the Development of Enteric Microcapsules for Posaconazole.Pharmaceutics · 2025Article
- Occurrence of Pathogenic and Allergenic Molds in the Outdoor and Indoor Environment of a Major Hospital and Molecular Epidemiology ofJournal of fungi (Basel, Switzerland) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
With over 300 million severe cases and 1.5 million deaths annually, invasive fungal diseases (IFDs) are a major medical burden and source of global morbidity and mortality. The World Health Organization (WHO) recently released the first-ever fungal priority pathogens list including 19 fungal pathogens, considering the perceived public health importance. Most of the pathogenic fungi are opportunistic and cause diseases in patients under immunocompromised conditions such as HIV infection, cancer, chemotherapy, transplantation, and immune suppressive drug therapy. Worryingly, the morbidity and mortality caused by IFDs are continuously on the rise due to the limited available antifungal therapies, the emergence of drug resistance, and the increase of population that is vulnerable to IFDs. Moreover, the COVID-19 pandemic worsened IFDs as a globe health threat as it predisposes the patients to secondary life-threatening fungi. In this mini-review, we provide a perspective on the advances and strategies for combating IFDs with antifungal therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.